艾昆纬（IQVIA）：2026从每日给药到长效制剂：管线创新如何重塑艾滋病治疗格局白皮书（英文版）（15页）.pdf

1、White PaperFrom Daily to Long-Acting:How Pipeline Innovation Could Reshape HIV TreatmentZACHERY G.BOWE,Assoc.Principal,Data,Technology,and Advisory Services,IQVIA SARAH W.RENNER,Consultant,Data,Technology,and Advisory Services,IQVIAAAKASH SONI,Assoc.Consultant,Data,Technology,and Advisory Services I

2、QVIAKEVIN M.CHERRY,Consultant,Data,Technology,and Advisory Services,IQVIASHIVA SHANMUGAM,Assoc.Principal,Data,Technology,and Advisory Services,IQVIASTEVEN I.GUBERNICK,Sr.Principal,Data,Technology,and Advisory Services,IQVIATable of contentsExecutive summary 1Key takeaways 1Introduction 2Promising pi

3、peline agents 3Current HIV market dynamics 5The Future of the HIV Market 6References 7Glossary 10About the authors 12 |1Executive summaryHIV treatment has advanced from complex,multi-pill regimens to once-daily single-tablet options that deliver durable viral suppression for many people living with

4、HIV(PLWH).Clinical efficacy and safety remains strong,but adherence continues to limit real-world outcomes,influenced by pill fatigue,stigma,side effects,and the cumulative friction of lifelong therapy.The next chapter of innovation is,therefore,shifting from marginal efficacy gains to practical imp

5、rovements,making treatment easier to start,easier to sustain,and easier to fit into everyday life.This white paper evaluates how long-acting(LA)regimens could reshape both HIV care and the competitive landscape.The review begins with the evolution of current standards of care,then assesses pipeline

6、programs designed to extend dosing from daily to weekly,monthly,and twice-yearly approaches across oral and injectable strategies.These advances are considered in the context of current market dynamics,including the continued dominance of daily oral regimens,the growing role of two-drug(2DR)approach